Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226200 · ClinicalTrials.gov registry record · NA
Soluble CD23 Expression in Asthma Patients Treated With OMA
A NA study, sponsored by University of Mississippi Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT00226200: Clinical Trial NA study, sponsored by University of Mississippi Medical Center.
NCT00226200 is a NA study that was terminated before completion, run by University of Mississippi Medical Center. The registered enrollment target is 80 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00226200, a NA study, was terminated before completion, sponsored by University of Mississippi Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study involves a FDA approved drug, Omalizumab, used in the treatment of moderate to severe allergic asthma that cannot be controlled by standard treatment. It works on IgE to control the allergic reaction. We are looking at the effects on non-allergic asthma. We hope to prove that Omalizumab will have the same effect on non-allergic asthmatics as it does allergic asthmatics.
Interventions
- DRUG Omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2004-11 |
| Est. Completion | 2007-10 |
| Phase | NA |
Why NCT00226200 stopped before completion
NCT00226200 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Omalizumab is the first listed.
NCT00226200 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00226200 about?
NCT00226200 is a clinical study titled "Soluble CD23 Expression in Asthma Patients Treated With OMA". This study involves a FDA approved drug, Omalizumab, used in the treatment of moderate to severe allergic asthma that cannot be controlled by standard treatment. It works on IgE to control the allergic reaction. We are looking at the effects on non-allergic asthma. We hope to prove that Omalizumab w...
What is the current status of trial NCT00226200?
This trial is currently terminated. It is a NA study. The enrollment target is 80 participants. The study started on 2004-11. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00226200?
The interventions under investigation include: Omalizumab (DRUG).
Who is sponsoring clinical trial NCT00226200?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00226200's enrollment target sits among peer trials
80 994th of 2000 higher than 941 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia